The New ALK Inhibitor: NVL-655 Expands Clinical Trial Sites
NVL-655 is a new experimental ALK inhibitor that is designed to treat ALK cancers, especially those that have become resistant to ALK inhibitors like Lorlatinib, Alectinib, and Brigatinib. This brain-penetrable drug not only addresses the typical ALK mutation, but it also targets compound mutations that tend to occur when there is tumor progression.
Those who have had progression on Lorlatinib, in the brain or elsewhere, would be good candidates for this trial.
The phase 1 (first in human) clinical trial of NVL-655 began in June 2022 in Nashville, Tennessee, USA. Additional sites enrolling now include Orange, California; Denver, Colorado; and Boston, Massachusetts, all in the U.S. There are sites planned in Detroit, Michigan; New York, New York; and Houston, Texas.
To find out more visit: A Study of NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Image courtesy of Nuvalent website. Please visit Nuvalent.com to read more about their approach.
It’s Lung Cancer Awareness Month, our time to educate people about ALK-Positive lung cancer. We have learned that anyone with lungs can get lung cancer, even young, healthy people with no risk factors. Now it’s time to tell others.
November is also a great month to raise money for ALK-positive lung cancer research. You can create a personal/team fundraising page on ALKPositive.org, then share your story with your contacts to encourage donations. You can also ask people to donate to ALKPositive.org even if you don’t have a personal fundraising team. A donation to the ALK Positive Research Fund makes a perfect holiday gift! The research that ALK Positive is funding now will create a pipeline for ground-breaking clinical trials in the future.
ALK LUNG CANCER CLINICAL TRIAL HELP AND SEARCHING
ALK Positive Support Group Clinical Trials Spreadsheet*
GO2 Foundation for Lung Cancer - LUNGMATCH
LUNGevity Online Clinical Trial Finder
CenterWatch Clinical Trials Search
MassiveBio Clinical Trials Search
General Info about ALK NSCLC Clinical Trials
As of October 2022, there are at least 50 clinical trials that are recruiting specifically for people with ALK-positive lung cancer. Many of these trials have multiple sites worldwide. Since ALK-positive lung cancer is a rare disease, it is difficult for any one oncologist to be aware of all the trials available. You can advocate for yourself and find a clinical trial that may be a good fit for you at any juncture in the treatment.
*The ALK Positive Clinical Trials Spreadsheet was developed by the ALK Positive Medical Committee. The database is updated monthly. Disclaimer: these trials have been consolidated by volunteers and should not be considered exhaustive. Listing of these trials is not an endorsement, and ALK Positive does not recommend one trial over another. Please talk with your doctor about these or any trials you are interested in.
Author: Ellee Urban